Regulatory Approvals

FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC

By

Regulatory Approvals — FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC  OncLive

Read the original at Regulatory Approvals ↗

Auto-published by the finit.news Events monitor from Regulatory Approvals; summarized by AI and may contain errors — verify against the primary source. July 22, 2026.

By

Related Post

Regulatory Approvals

FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC

Regulatory Approvals

FDA Approves Zidesamtinib for Specific Type of Lung Cancer – respiratory

Regulatory Approvals

FDA Takes Further Steps to Remove Outdated Authorizations for Color Additives in Food

Financial News For All

Regulatory Approvals

FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC

Regulatory Approvals

FDA Approves Zidesamtinib for Specific Type of Lung Cancer – respiratory

Regulatory Approvals

FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC

Regulatory Approvals

FDA Approves Zidesamtinib for Previously Treated ROS1-Positive NSCLC